| Literature DB >> 32308732 |
Erdan Luo1, Daiyan Zhang1, Hua Luo1, Bowen Liu1, Keming Zhao2,3, Yonghua Zhao1, Ying Bian1, Yitao Wang1.
Abstract
BACKGROUND: A novel coronavirus was identified in December, 2019 in Wuhan, China, and traditional Chinese medicine (TCM) played an active role in combating the novel coronavirus pneumonia (NCP) caused by this fast-spreading virus COVID-19. Thus, we aimed to explore TCM characteristics of clinical efficacy to NCP, as well as to optimize Qingfei Paidu decoction (QFPDD) and the recommended formulas to NCP by National Health Commission (NHC).Entities:
Keywords: Empirical study; Novel coronavirus pneumonia; Traditional Chinese Medicine; Treatment efficacy; Wuhan China
Year: 2020 PMID: 32308732 PMCID: PMC7156896 DOI: 10.1186/s13020-020-00317-x
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 5.455
Fig. 1Diagram of pathological evolution of TCM
Characteristics of TCM Pathogenesis in NCP and SARS
| NCP (COVID-19) | SARS | |
|---|---|---|
| Original area | Wuhan, Hubei | Foshan, Guangdong |
| Onset time | Nov, 2019 | Nov, 2002 |
| TCM pathogen | Dampness toxin | Epidemic toxin (疫毒) |
| Main symptoms | Low fever or no fever, some patients only felt fatigue, or dry cough, nausea, diarrhea. Severe dyspnea occurs 1 week later, which can lead to multiple organs failure. | The typical symptom is fever (frequent high fever), following fatigue, head and muscle pain. Some patients present dry cough, less sputum after 3 to 6 days, as well as chest discomfort and wheezing. In severe stage, the occurrence of gasp and acute respiratory distress. |
| Location of disease | Lungs, involving spleen and stomach, eventually affecting heart, liver and kidney | Mainly in lung |
| Pathological evolutional periods | 1 Medical observation period: fatigue and gastrointestinal dysfunction or fever 2 Clinical period when diagnosed 2.1 Mild type: syndrome of cold dampness obstructing lung (寒湿郁肺), syndrome of lung with dampness heat retention (湿热蕴肺证) 2.2 Moderate type: syndrome of lung with dampness toxin retention (湿毒郁肺证), syndrome of cold dampness blocking lung (寒湿阻肺证) 2.3 Severe type: syndrome of pestilent toxin blocking lung (疫毒闭肺证), syndrome of dual blaze of Qi and blood (气血两燔证) 2.4 Critical type: syndrome of internal block and external collapse (内闭外脱证) 3 Recovery period: syndrome of Qi and Yin deficiency in lung and spleen (肺脾气阴两虚证) | 1 Early stage: syndrome of epidemic toxin invading lung (疫毒犯肺证) 2 Progressive stage: syndrome of epidemic toxin obstructing lung (疫毒壅肺), syndrome of blocking lung with severe dyspnea (肺闭喘憋), syndrome of internal block and external collapse (内闭外脱证) 3 Recovery period: syndrome of Qi and Yin deficiency (气阴两虚证), syndrome of phlegm and blood stasis blocking collaterals (痰瘀阻络证). |
Demographic characteristics and TCM features of patients
| Characteristic | Population |
|---|---|
| Gender | |
| Male | 34 |
| Female | 20 |
| Age | |
| < 45 | 11 |
| [45, 60) | 21 |
| [60, 75) | 18 |
| ≥ 75 | 4 |
| Symptoms | |
| Fever | 16 |
| Cough | 24 |
| Shortness of breath | 18 |
| Abnormal digestion | 5 |
| Anorexia | 8 |
| Tongue manifestation | |
| Red tongue with white coating (舌红苔白) | 24 |
| Red tongue with yellow coating (舌红苔黄) | 11 |
| Others | 16 |
| Pulse manifestation | |
| Deep pulse (沉脉) | 19 |
| Slippery pulse (滑脉) | 12 |
| Others | 20 |
Relevant of Symptoms and TCM clinical features
| Fever | Cough | Shortness of breath | Abnormal digestion | Anorexia | Red tongue with white coating | Deep pulse | |
|---|---|---|---|---|---|---|---|
| Fever | 1 | − 0.299a | − 0.411b | 0.346a | 0.057 | 0.316a | 0.450b |
| Cough | − 0.299a | 1 | − 0.203 | − 0.311a | − 0.083 | − 0.056 | − 0.024 |
| Shortness of breath | − 0.411b | − 0.203 | 1 | 0.032 | 0.02 | − 0.15 | − 0.406b |
| Abnormal digestion | 0.346a | − 0.311a | 0.032 | 1 | 0.039 | − 0.016 | 0.234 |
| Anorexia | 0.057 | − 0.083 | 0.02 | 0.039 | 1 | − 0.17 | − 0.175 |
| Red tongue with white coating | 0.316a | − 0.056 | − 0.15 | − 0.016 | − 0.17 | 1 | 0.639b |
| Deep pulse | 0.450b | − 0.024 | − 0.406b | 0.234 | − 0.175 | 0.639b | 1 |
aCorrelation significant, at 0.05 level; bat 0.01 level
The most frequently used CMs for NCP patients
| Classification of TCM | Top 3 used TCMs | Frequency |
|---|---|---|
| Category of clearing heat and drying dampness and removing toxin (清热燥湿解毒类) | 29 | |
| 11 | ||
| 10 | ||
| Category of aromatic herbs resolving dampness (芳香化湿类) | 28 | |
| 12 | ||
| 9 | ||
| Category of eliminating dampness with bland medicinal (淡渗利湿类) | 40 | |
| 34 | ||
| 36 | ||
| Category of invigorating spleen and removing dampness (ISRD, 健脾祛湿类) | 30 | |
| 5 | ||
| 2 | ||
| Category of power appetite and digestant medicinal (开胃消食类) | 19 | |
| 18 | ||
| 13 | ||
| Others | 33 | |
| 27 | ||
| 27 |
Assignment of independent variables in multiple linear regression
| Variables | Assignment |
|---|---|
| X1: Age | Continuous variable |
| X2: Gender | Male = 1, Female = 0 |
| X3: Cough | Yes = 1, No = 0 |
| X4: Short of breath | Yes = 1, No = 0 |
| X5: Administrate category of clearing heat and drying dampness and removing toxin | Yes = 1, No = 0 |
| X6: Administrate category of aromatic herbs resolving dampness | Yes = 1, No = 0 |
| X7: Administrate category of ISRD | Yes = 1, No = 0 |
| X8: Administrate other CMs | Yes = 1, No = 0 |
Regression coefficients in multiple linear regression
| Variable | Unstandardized coefficient | Standardized coefficient | Collinearity | ||||
|---|---|---|---|---|---|---|---|
| B | S.E. | Beta | Tolerance | VIF | |||
| (Constant) | − 4.999 | 3.956 | − 1.264 | 0.224 | |||
| X1: | 0.106 | 0.054 | 0.446 | 1.963 | 0.067 | 0.522 | 1.914 |
| X2: | 4.538 | 1.565 | 0.727 | 2.899 | 0.010* | 0.428 | 2.336 |
| X3: | − 3.474 | 1.430 | − 0.580 | − 2.430 | 0.027* | 0.474 | 2.110 |
| X4: | − 2.665 | 1.311 | − 0.436 | − 2.033 | 0.059 | 0.586 | 1.707 |
| X5: | 1.925 | 1.442 | 0.309 | 1.335 | 0.201 | 0.504 | 1.983 |
| X6: | − 1.510 | 1.409 | − 0.242 | − 1.072 | 0.300 | 0.529 | 1.892 |
| X7: | 7.864 | 2.291 | 1.051 | 3.433 | 0.003** | 0.288 | 3.474 |
| X8: | 9.771 | 2.781 | 0.885 | 3.514 | 0.003** | 0.425 | 2.355 |
*P < 0.5, **P < 0.01
Values of blood test when admission and discharge of hospital
| Reference values | Observed values in average (95%CI) | ||||
|---|---|---|---|---|---|
| WBC (*109/L) | 4–10 | Admission | 4.73 (3.97–5.49) | − 3.394 | 0.004** |
| Discharge | 6.68 (5.88–7.47) | ||||
| Neu % | 50–70 | Admission | 71.41 (65.65–77.16) | 0.319 | 0.754 |
| Discharge | 71.62 (67.37–75.87) | ||||
| Lym % | 20–40 | Admission | 21.30 (16.18–26.42) | 0.016 | 0.987 |
| Discharge | 20.28 (16.55–24.01) | ||||
| Mon % | 3–12 | Admission | 6.55 (5.02–8.09) | − 0.561 | 0.583 |
| Discharge | 6.90 (5.34–8.46) | ||||
| EOS % | 0.5–5 | Admission | 0.54 (0.21–0.87) | − 2.800 | 0.013* |
| Discharge | 0.99 (0.70–1.28) | ||||
| Bas % | 0–1 | Admission | 0.20 (0.12–0.28) | − 0.968 | 0.347 |
| Discharge | 0.21 (0.14–0.29) | ||||
| Neu# (*109/L) | 2–7 | Admission | 3.45 (2.69–4.21) | − 2.359 | 0.031* |
| Discharge | 4.84 (4.06–5.62) | ||||
| Lym# (*109/L) | 0.8–4 | Admission | 0.94 (0.74–1.14) | − 2.948 | 0.009** |
| Discharge | 1.30 (1.09–1.51) | ||||
| Mon# (*109/L) | 0.12–1.2 | Admission | 0.31 (0.22–0.40) | − 1.897 | 0.076 |
| Discharge | 0.46 (0.32–0.61) | ||||
| Eos# (*109/L) | 0.02–0.5 | Admission | 0.02 (0.01–0.04) | − 4.592 | 0.000*** |
| Discharge | 0.06 (0.05–0.08) | ||||
| Bas# (*109/L) | 0–0.1 | Admission | 0.00 (0.00–0.01) | − 3.846 | 0.001** |
| Discharge | 0.01 (0.01–0.02) | ||||
| RBC (*1012/L) | 4–5.5 | Admission | 4.47 (4.21–4.73) | 4.971 | 0.000*** |
| Discharge | 4.03 (3.76–4.30) | ||||
| HGB (g/L) | 120–160 | Admission | 137.40 (128.85–145.95) | 5.067 | 0.000*** |
| Discharge | 123.53 (114.27–132.80) | ||||
| HCT (%) | 35–51 | Admission | 42.12 (39.52–44.72) | 4.972 | 0.000*** |
| Discharge | 38.05 (35.37–40.72) | ||||
| MCV (fL) | 80–100 | Admission | 94.29 (92.54–96.04) | − 0.469 | 0.645 |
| Discharge | 94.38 (92.86–95.90) | ||||
| MCH (g/L) | 320–360 | Admission | 326.13 (322.83–329.44) | 1.070 | 0.301 |
| Discharge | 324.40 (319.66–329.14) | ||||
| PLT (*109/L) | 100–300 | Admission | 186.80 (150.28–223.32) | − 4.598 | 0.000*** |
| Discharge | 299.80 (261.20–338.40) | ||||
| MPV (fL) | 6.5–12 | Admission | 9.00 (8.55–9.45) | 5.009 | 0.000*** |
| Discharge | 8.27 (7.82–8.71) | ||||
| PDW (%) | 9–17 | Admission | 16.00 (15.79–16.21) | 1.464 | 0.164 |
| Discharge | 15.87 (15.67–16.06) | ||||
| PCT (%) | 0.108–0.280 | Admission | 0.16 (0.14–0.19) | − 4.014 | 0.001** |
| Discharge | 0.25 (0.22–0.28) | ||||
*P < 0.5, **P < 0.01, ***P < 0.001
Fig. 2Active compounds (C)-putative targets (T) network of five disease stages
Fig. 3Active compounds (C)-putative targets (T) network of QFPDD
Fig. 4The bubble diagram of KEGG pathway enrichment analysis
Fig. 5The major advantages and key mechanisms of TCM on the treatment of NCP